Literature DB >> 19499520

Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury.

Dolores B Njoku1, Zhaoxia Li, Nicole D Washington, Jenelle L Mellerson, Monica V Talor, Rajni Sharma, Noel R Rose.   

Abstract

The pathogenesis of immune-mediated drug-induced liver injury (DILI) following halogenated anesthetics, carbamazepine or alcohol has not been fully elucidated. Detecting cytochrome P450 2E1 (CYP2E1) IgG4 auto-antibodies in anesthetic DILI patients suggests a role for IL-4 in this hapten-mediated process. We investigated IL-4-mediated mechanisms using our model of experimental DILI induced by immunizing BALB/c (WT) and IL-4(-/-) (KO) mice with S100 liver proteins covalently modified by a trifluoroacetyl chloride (TFA) hapten formed following halogenated anesthetic metabolism by CYP2E1. WT mice developed more hepatitis, TFA and S100 antibodies (p<0.01), as well as T-cell proliferation to CYP2E1 and TFA (p<0.01) than KO mice. Additionally, WT CD4(+) T cells adoptively transferred hepatitis to naïve Rag(-/-) mice (p<0.01). Pro-inflammatory cytokines were expectedly decreased in TFA hapten-stimulated KO splenocyte supernatants (p<0.001); however, IL-2 and IFN-gamma (p<0.05), as well as IL-6 and IL-10 (p<0.001) levels were elevated in CYP2E1-stimulated KO splenocyte supernatants, suggesting dual IL-4-mediated pro-inflammatory and regulatory responses. Anti-IL-10 administered to KO mice increased hepatitis, TFA and CYP2E1 antibodies in KO mice confirming a critical role for IL-4. This is the first demonstration of dual roles for IL-4 in the pathogenesis of immune-mediated DILI by suppressing auto-antigen-induced regulatory responses while promoting hapten-induced pro-inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19499520      PMCID: PMC2737704          DOI: 10.1002/eji.200838135

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  38 in total

1.  Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions.

Authors:  N Franklin Adkinson; David Essayan; Rebecca Gruchalla; Helen Haggerty; Thomas Kawabata; J David Sandler; Lawrence Updyke; Neil H Shear; Daniel Wierda
Journal:  J Allergy Clin Immunol       Date:  2002-03       Impact factor: 10.793

Review 2.  Autoimmune hepatitis: the way we were, the way we are today and the way we hope to be.

Authors:  Ian R Mackay; Ban-Hock Toh
Journal:  Autoimmunity       Date:  2002-08       Impact factor: 2.815

3.  IL-4-deficient mice develop less acute but more chronic relapsing collagen-induced arthritis.

Authors:  Lars Svensson; Kutty Selva Nandakumar; Asa Johansson; Liselotte Jansson; Rikard Holmdahl
Journal:  Eur J Immunol       Date:  2002-10       Impact factor: 5.532

4.  Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists.

Authors:  Dolores B Njoku; Robert S Greenberg; Mohammed Bourdi; Craig B Borkowf; Elizabeth M Dake; Jackie L Martin; Lance R Pohl
Journal:  Anesth Analg       Date:  2002-02       Impact factor: 5.108

5.  Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.

Authors:  George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee
Journal:  Ann Intern Med       Date:  2002-12-17       Impact factor: 25.391

6.  Halothane-induced liver injury in outbred guinea pigs: role of trifluoroacetylated protein adducts in animal susceptibility.

Authors:  M Bourdi; H R Amouzadeh; T H Rushmore; J L Martin; L R Pohl
Journal:  Chem Res Toxicol       Date:  2001-04       Impact factor: 3.739

7.  Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease.

Authors:  Yasuhiro Masubuchi; Mohammed Bourdi; Timothy P Reilly; Mary Louise M Graf; John W George; Lance R Pohl
Journal:  Biochem Biophys Res Commun       Date:  2003-04-25       Impact factor: 3.575

8.  I kappa B kinase 2/beta deficiency controls expansion of autoreactive T cells and suppresses experimental autoimmune encephalomyelitis.

Authors:  Bernhard Greve; Robert Weissert; Nada Hamdi; Estelle Bettelli; Raymond A Sobel; Anthony Coyle; Vijay K Kuchroo; Klaus Rajewsky; Marc Schmidt-Supprian
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

9.  Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice.

Authors:  Alfred R Oliver; Geoffrey M Lyon; Nancy H Ruddle
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

10.  Desflurane hepatitis associated with hapten and autoantigen-specific IgG4 antibodies.

Authors:  James S Anderson; Noel R Rose; Jackie L Martin; Edmond I Eger; Dolores B Njoku
Journal:  Anesth Analg       Date:  2007-06       Impact factor: 5.108

View more
  11 in total

1.  Endogenous interleukin-4 regulates glutathione synthesis following acetaminophen-induced liver injury in mice.

Authors:  Pauline M Ryan; Mohammed Bourdi; Midhun C Korrapati; William R Proctor; Ronald A Vasquez; Steven B Yee; Timothy D Quinn; Mala Chakraborty; Lance R Pohl
Journal:  Chem Res Toxicol       Date:  2011-12-13       Impact factor: 3.739

Review 2.  STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver.

Authors:  Bin Gao; Hua Wang; Fouad Lafdil; Dechun Feng
Journal:  J Hepatol       Date:  2012-04-12       Impact factor: 25.083

Review 3.  Tolerogenic dendritic cells and myeloid-derived suppressor cells: potential for regulation and therapy of liver auto- and alloimmunity.

Authors:  Sudha Natarajan; Angus W Thomson
Journal:  Immunobiology       Date:  2010-06-22       Impact factor: 3.144

Review 4.  Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review.

Authors:  Dolores B Njoku
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-05       Impact factor: 4.481

5.  Interleukin-4 deficiency protects mice from acetaminophen-induced liver injury and inflammation by prevention of glutathione depletion.

Authors:  Daniele Araújo Pires; Pedro Elias Marques; Rafaela Vaz Pereira; Bruna Araújo David; Lindisley Ferreira Gomides; Ana Carolina Fialho Dias; Albená Nunes-Silva; Vanessa Pinho; Denise Carmona Cara; Leda Quercia Vieira; Mauro Martins Teixeira; Gustavo Batista Menezes
Journal:  Inflamm Res       Date:  2013-10-08       Impact factor: 4.575

Review 6.  Drug-induced hepatotoxicity: metabolic, genetic and immunological basis.

Authors:  Dolores B Njoku
Journal:  Int J Mol Sci       Date:  2014-04-22       Impact factor: 5.923

7.  In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity.

Authors:  Merylin Cottagiri; Maeva Nyandjo; Matthew Stephens; Joel J Mantilla; Hirohisa Saito; Ian R Mackay; Noel R Rose; Dolores B Njoku
Journal:  Cell Mol Immunol       Date:  2018-07-20       Impact factor: 11.530

8.  Sex bias in experimental immune-mediated, drug-induced liver injury in BALB/c mice: suggested roles for Tregs, estrogen, and IL-6.

Authors:  Joonhee Cho; Lina Kim; Zhaoxia Li; Noel R Rose; Monica Vladut Talor; Dolores B Njoku
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

9.  DNA-PKcs Inhibition Extends Allogeneic Skin Graft Survival.

Authors:  David K Harrison; Zachary J Waldrip; Lyle Burdine; Sara C Shalin; Marie Schluterman Burdine
Journal:  Transplantation       Date:  2021-03-01       Impact factor: 5.385

10.  Identification of a Shared Cytochrome p4502E1 Epitope Found in Anesthetic Drug-Induced and Viral Hepatitis.

Authors:  Elisa K McCarthy; Amanda Vakos; Merylin Cottagiri; Joel J Mantilla; Lakshmi Santhanam; David L Thomas; L Mario Amzel; Noel R Rose; Dolores B Njoku
Journal:  mSphere       Date:  2018-10-10       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.